Gufic BioSciences Reports Mixed Financial Results Amid Rising Interest Expenses in August 2025
Gufic BioSciences reported its financial results for the quarter ending June 2025, highlighting its highest quarterly net sales in five quarters at Rs 223.72 crore. However, the company experienced declines in both Profit Before Tax and Profit After Tax, alongside a significant increase in interest expenses due to higher borrowings.
Gufic BioSciences, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The results, declared on August 13, 2025, indicate a complex financial landscape for the company.On a positive note, Gufic BioSciences achieved its highest quarterly net sales in the last five quarters, reaching Rs 223.72 crore. This uptick in sales suggests a favorable near-term sales trend. However, the company faces challenges as evidenced by its Profit Before Tax (PBT) and Profit After Tax (PAT) figures. The PBT for the quarter stood at Rs 16.34 crore, reflecting a notable decline compared to the average of the previous four quarters, which was Rs 22.63 crore. Similarly, the PAT of Rs 13.07 crore also showed a decrease against the average of Rs 17.42 crore from the prior quarters.
Additionally, the interest expense for the latest six months has risen significantly, indicating increased borrowings, with a growth of 74.73% over the previous half-year period. This adjustment in evaluation reflects the ongoing financial dynamics within Gufic BioSciences.
For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
